Making biological drugs with spider silk protein
[PRESS RELEASE 2017-05-23] Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk. Animal studies reveal it to be just as effective as the biological drugs currently in clinical use. The study is published in Nature Communications.
Surfactant revolutionised the care of preterm babies by reducing the surface tension in their pulmonary alveoli and allowing them to be inflated at the moment of birth. Curosurf, the most globally widespread drug, was developed by scientists at Karolinska Institutet in the 1970s and 1980s. The drug is produced by the isolation of proteins from pig lungs, a process that is expensive, complicated and potentially risky. Researchers at Karolinska Institutet and their colleagues from the University of Riga amongst other institutions, have now developed a surfactant drug that can be produced much more simply and cheaply using spider protein.
“The manufacturing process is based on the method spiders use to keep their extremely easily aggregated proteins soluble for silk-spinning,” explains Professor Jan Johansson at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society. “We chose to produce lung surfactant protein C because it is probably the world’s most aggregation-inclined protein.”
By applying this method, the researchers have managed to produce a range of potential biological drugs using the part of the spider protein that ensures that the proteins remain soluble, namely the N-terminal domain.
“We had bacteria produce this part of the protein and then linked it to different protein drug candidates,” says docent Anna Rising at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society who co-led the study with Professor Johansson.
The researchers also compared their synthetic lung surfactant with the biological analogue currently on the market and found it equally effective at reducing the surface tension in an animal model of neonate respiratory disorders.
“Since this production method is much simpler and cheaper, it might one day be possible to use our synthetic lung surfactant to treat more lung diseases than just preterm babies,” adds Professor Johansson. “The method will also hopefully enable the production of other biological drugs.”
The study was primarily financed by the Swedish Research Council and was performed in collaboration with the Italian pharmaceutical company Chiesi Farmaceutici.
Publication: “Efficient protein production inspired by how spiders make silk”. Nina Kronqvist, Médoune Sarr, Anton Lindqvist, Kerstin Nordling, Martins Otikovs, Luca Venturi, Barbara Pioselli, Pasi Purhonen, Michael Landreh, Henrik Biverstål, Zigmantas Toleikis, Lisa Sjöberg, Carol V. Robinson, Nicola Pelizzi, Hans Jörnvall, Hans Hebert, Kristaps Jaudzems, Tore Curstedt, Anna Rising & Jan Johansson. Nature Communications, online 23 May 2017.
For more information, please contact:
Jan Johansson, professor
Department of Neurobiology, Care Sciences and Society
Phone: +46 (0)70 345 70 48
Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.